A Prescribed Risk: The Fatal Consequences of Unapproved Anti-Ageing Peptides

When an aging martial artist and Hollywood stuntman seeks physical optimization in a syringe, the boundary between cutting-edge therapy and fatal risk quickly blurs. The death of 75-year-old Richard Norton—a veteran fight choreographer who once shared screens with Chuck Norris and guarded David Bowie—has brought Australia’s medical regulatory framework under sharp scrutiny.

In March 2025, Norton turned to Melbourne medical practitioner Dr Jerzy Muchnicki for peptide therapy. Suffering from fatigue, shoulder pain, and muscle loss—for which another doctor had previously prescribed similar compounds—Norton sought relief through synthetic chemistry. Following baseline blood tests and an informed consent process acknowledging the experimental nature of the treatment, Muchnicki prescribed CJC1295 and ipamorelin on March 19.

The initial results appeared promising. Within a week, Norton reported feeling better and experiencing symptom relief. Yet the pursuit of physical recovery took a sudden turn toward excess when he admitted to administering double the prescribed dosage of both substances.

Upon learning of the doubled dose on March 28, a nurse advised him to return to the standard amount the following week. That same day, Muchnicki added two more peptides to the regimen. Hours after injecting CJC1295 and ipamorelin, Norton flushed, lost consciousness, and subsequently died at the Alfred hospital on March 30.

The subsequent investigation revealed an unsettling disconnect between clinical practice and regulatory oversight. An independent expert reviewing the case for the Medical Board of Australia noted that evidence for the safety or efficacy of CJC1295 and ipamorelin in humans remains virtually non-existent. In addition, Muchnicki’s record-keeping was criticized as sparse, inadequate, and far below acceptable standards.

Yet the institutional response was surprisingly mild. The Medical Board determined that formal sanctions were unnecessary after Muchnicki acknowledged his errors, accepted accountability, expressed sorrow, and pledged to stop prescribing unapproved peptides. His penalty was limited to mandatory one-on-one coaching in clinical record management.

Now, Victorian coroner David Ryan is calling for systemic intervention, urging the Therapeutic Goods Administration to reevaluate these unapproved compounds entirely. Ryan recommended shifting peptides from Schedule 4, which permits prescription by any doctor, to Schedule 10, restricting them strictly to clinical trials and experimental use. As the coroner observed in his findings, I am not satisfied that it is appropriate for them to be available to be prescribed by medical practitioners.

The Therapeutic Goods Administration routinely warns consumers against importing unapproved peptides promoted online for anti-ageing, muscle growth, and recovery. However, Norton’s case highlights a deeper systemic reality. Unproven chemical cocktails can still be legally prescribed by willing doctors long before regulators decide to act.

Written by Thorben Thiede thorben.thiede@alpineweekly.com